3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
82
Leukemia, Myeloid, Chronic-Phase
22
Leukemia
21
Gastrointestinal Stromal Tumors
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Neoplasms
8
Blast Crisis
7
Neoplasm Metastasis
6
Philadelphia Chromosome
4
Myeloproliferative Disorders
4
Melanoma
4
Leukemia, Myeloid
4
Bone Marrow Diseases
4
Recurrence
3
Leukemia, Myeloid, Acute
3
Hematologic Diseases
3
Bronchiolitis Obliterans Syndrome
3
Synovitis, Pigmented Villonodular
2
Ovarian Neoplasms
2
Neoplasm, Residual
2
Leukemia, Myeloid, Accelerated Phase
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Substance Withdrawal Syndrome
1
Sarcoma
1
Retroperitoneal liposarcoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Piebaldism
1
Peritoneal Neoplasms
1
Neurofibromatoses
1
Interventions
pembrolizumab
2
Pemetrexed
2
nilotinib
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
Zoledronic Acid
1
Trastuzumab
1
Radiosurgery
1
MRX-2843
1
Everolimus
1
Electrochemotherapy
1
Denosumab
1
Cisplatin
1
Carboplatin
1
Bleomycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplastic Processes
×
nilotinib
×
Clear all
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA